BTIG Reiterates Buy on Opus Genetics, Maintains $12 Price Target

Opus Genetics, Inc.

Opus Genetics, Inc.

IRD

0.00

BTIG analyst Thomas Shrader reiterates Opus Genetics (NASDAQ: IRD) with a Buy and maintains $12 price target.